Research progress of cryoablation in the treatment of lung cancer

doi:10.3760/cma.j.issn.1673-422X.2019.07.008

Abstract

Ma Yuankun, Ni Jixiang, Zhao Tianming, Hu Xuehua, Yang Yuting. Research progress of cryoablation in the treatment of lung cancer[J]. Journal of International Oncology, 2019, 46(7): 427-429.

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394424. DOI: 10.3322/caac.21492. ［2］麦泽锋. 消癌平注射液联合多西他赛治疗晚期非小细胞肺癌的临床观察［J］. 国际肿瘤学杂志, 2017, 44(7): 557558. DOI: 10.3760/cma.j.issn.1673422X.2017.07.021. ［3］ Jia B, Zheng Q, Qi X, et al. Survival comparison of right and left side nonsmall cell lung cancer in stage ⅠⅢA patients: a surveillance epidemiology and end results (SEER) analysis［J］. Thorac Cancer, 2019, 10(3): 459471. DOI: 10.1111/17597714.12959. ［4］ Knavel EM, Brace CL. Tumor ablation: common modalities and general practices［J］. Tech Vasc Interv Radiol, 2013, 16(4): 192200. DOI: 10.1053/j.tvir.2013.08.002. ［5］ Mehta A, Oklu R, Sheth RA. Thermal ablative therapies and immune checkpoint modulation: can locoregional approaches effect a systemic response?［J］. Gastroenterol Res Pract, 2016, 2016: 9251375. DOI: 10.1155/2016/9251375. ［6］ Abdo J, Cornell DL, Mittal SK, et al. Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers［J］. Front Oncol, 2018, 8: 85. DOI: 10.3389/fonc.2018.00085. ［7］ Yamauchi Y, Izumi Y, Hashimoto K, et al. Percutaneous cryoablation for the treatment of medically inoperable stage Ⅰ nonsmall cell lung cancer［J］. PLoS One, 2012, 7(3): e33223. DOI: 10.1371/journal.pone.0033223. ［8］ Moore W, Talati R, Bhattacharji P, et al. Fiveyear survival after cryoablation of stage Ⅰ nonsmall cell lung cancer in medically inoperable patients［J］. J Vasc Interv Radiol, 2015, 26(3): 312319. DOI: 10.1016/j.jvir.2014.12.006. ［9］ Sharma A, Abtin F, Shepard JA. Imageguided ablative therapies for lung cancer［J］. Radiol Clin North Am, 2012, 50(5): 975999. DOI: 10.1016/j.rcl.2012.06.004. ［10］赵丹, 乔炳礼, 李润花, 等. 氩氦刀冷冻消融联合化疗治疗非小细胞肺癌的疗效及对相关癌性疼痛的影响［J］. 实用医学杂志, 2016, 32(21): 34793482. DOI: 10.3969/j.issn.10065725.2016.21.005. ［11］孔小锋, 姚飞, 陈继冰, 等. 经皮联合支气管腔内冷冻消融治疗中央型肺癌的研究分析［J］. 中华肺部疾病杂志(电子版), 2014, 7(2): 174178. DOI: 10.3969/cma.j.issn.16746902.2014.02.011. ［12］ Ridge CA, Solomon SB. Percutaneous ablation of colorectal lung metastases［J］. J Gastrointest Oncol, 2015, 6(6): 685692. DOI: 10.3978/j.issn.20786891.2015.095. ［13］ Ridge CA, Solomon SB, Thornton RH. Thermal ablation of stage Ⅰ nonsmall cell lung carcinoma［J］. Semin Intervent Radiol, 2014, 31(2): 118124. DOI: 10.1055/s00341373786. ［14］ Yamauchi Y, Izumi Y, Kawamura M, et al. Percutaneous cryoablation of pulmonary metastases from colorectal cancer［J］. PLoS One, 2011, 6(11): e27086. DOI: 10.1371/journal.pone.0027086. ［15］ de Baere T, Tselikas L, Woodrum D, et al. Evaluating cryoablation of metastatic lung tumors in patients—safety and efficacy: the ECLIPSE trial—interim analysis at 1year［J］. J Thorac Oncol, 2015, 10(10): 14681474. DOI: 10.1097/JTO.0000000000000632. ［16］ Zappa C, Mousa SA. Nonsmall cell lung cancer: current treatment and future advances［J］. Transl Lung Cancer Res, 2016, 5(3): 288300. DOI: 10.21037/tlcr.2016.06.07. ［17］ Zhang M, Guo H, Zhao S, et al. Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced nonsmall cell lung cancer: a metaanalysis of randomized controlled trials［J］. Oncotarget, 2016, 7(26): 3982339833. DOI: 10.18632/oncotarget.9503. ［18］ Yang Y, Zhang B, Li R, et al. EGFRtyrosine kinase inhibitor treatment in a patient with advanced nonsmall cell lung cancer and concurrent exon 19 and 21 EGFR mutations: a case report and review of the literature［J］. Oncol Lett, 2016, 11(5): 35463550. DOI: 10.3892/ol.2016.4409. ［19］ Gao W, Guo Z, Shu S, et al. The application effect of percutaneous cryoablation for the stage ⅢB/Ⅳ advanced nonsmallcell lung cancer after the failure of chemoradiotherapy［J］. Asian J Surg, 2018, 41(6): 530536. DOI: 10.1016/j.asjsur.2018.02.006. ［20］洪超煜, 梅同华, 王进. 化疗间插联合EGFRTKIs对比单独化疗一线治疗晚期非小细胞肺癌的meta分析［J］. 中国肺癌杂志, 2016, 19(12): 837846. DOI: 10.3779/j.issn.10093419.2016.12.06. ［21］ Chang TC, Chin YT, Nana AW, et al. Enhancement by nanodiaminotetrac of antiproliferative action of gefitinibon colorectal cancer cells: mediation by EGFR sialylation and PI3K activation［J］. Horm Cancer, 2018, 9(6): 420432. DOI: 10.1007/s126720180341x. ［22］ Sohn HS, Kwon JW, Shin S, et al. Effect of smoking status on progressionfree and overall survival in nonsmall cell lung cancer patients receiving erlotinib or gefitinib: a metaanalysis［J］. J Clin Pharm Ther, 2015, 40(6): 661671. DOI: 10.1111/jcpt.12332. ［23］ Gu XY, Jiang Z, Fang W. Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced nonsmall cell lung cancer［J］. J Int Med Res, 2011, 39(5): 17361743. DOI: 10.1177/147323001103900516. ［24］ Inoue M, Nakatsuka S, Jinzaki M. Cryoablation of earlystage primary lung cancer［J］. Biomed Res Int, 2014, 2014: 521691. DOI: 10.1155/2014/521691. ［25］ Chou HP, Chen CK, Shen SH, et al. Percutaneous cryoablation for inoperable malignant lung tumors: midterm results［J］. Cryobiology, 2015, 70(1): 6065. DOI: 10.1016/j.cryobiol.2014.12.004. ［26］ Abdo J, Cornell DL, Mittal SK, et al. Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers［J］. Front Oncol, 2018, 8: 85. DOI: 10.3389/fonc.2018.00085.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[3]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[4]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[5]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[6]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[7]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[8]	Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301.
[9]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251.
[10]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[11]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 111-115.
[12]	Huang Huayu, Song Qibin, Gong Hongyun, Song Jia. Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy [J]. Journal of International Oncology, 2022, 49(12): 718-723.
[13]	Zhang Hongjiao, Jiang Jie, Huang Wei. Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis [J]. Journal of International Oncology, 2022, 49(1): 51-55.
[14]	Hu Ge, Su Jie, Li Qiangwei, Xu Peng, Xu Xiuli, Qian Xiaotao. Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer [J]. Journal of International Oncology, 2021, 48(9): 523-526.
[15]	Wang Jun, Zhao Xia, Li Haifei, Zhang Cheng. Clinic diagnostic value of MSCT imaging features in nodular lung adenocarcinoma subtype [J]. Journal of International Oncology, 2021, 48(9): 537-543.

Research progress of cryoablation in the treatment of lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments